BMS Presents 4-Year Data from Phase III DASISION Trial
Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc. have announced 4-year follow-up data from the Phase III DASISION study of Sprycel (dasatinib) 100 mg once daily versus imatinib (400 mg daily) in the first-line treatment of adults with Philadelphia chromosome-positive (Ph+) chronic phase chronic myeloid leukemia (CP-CML).
At 4 years, 76% of Sprycel patients versus 63% of imatinib patients achieved a major molecular response (MMR).1,2 In addition, 84% of Sprycel patients versus 64% of imatinib patients achieved BCR-ABL ≤10% at 3 months, which is considered an optimal molecular response as defined by treatment guidelines (2013 European LeukemiaNet guidelines).
Patients in both arms who achieved this response at 3 months had improved overall survival (OS) and progression-free survival (PFS) at 4 years versus. those who did not. At 4 years, 67% of Sprycel patients (n=172) and 65% of imatinib patients (n=168) remained on treatment. These data were presented at the 55th Annual Meeting of the American Society of Hematology (Abstract #653).
Most drug-related adverse events occurred within the first year of treatment, and the types of safety events were consistent through year four. Adverse reactions reported in ≥10% of Sprycel-treated patients with newly diagnosed CP Ph+ CML were myelosuppression, fluid retention events (pleural effusion and superficial localised edema), diarrhea, headache, musculoskeletal pain, rash, and nausea. In Sprycel-treated patients, most grade 3–4 adverse events were hematologic lab abnormalities and occurred within the first year.
“These findings are based on 4 years of follow-up in patients and provide additional insights regarding the safety and efficacy of Sprycel in newly-diagnosed Ph+ CP-CML patients,” said Dr Jorges E. Cortes, University of Texas MD Anderson Cancer Center. “These data also offer important insights on the potential impact that early responses might have on patient outcomes in this setting.”
“This longer term analysis from our Phase III trial provides further evidence of the sustained efficacy of Sprycel in the first-line setting and adds to our understanding of its safety in patients treated for several years,” said Michael Giordano, senior vice president, Head of Development, Oncology & Immunology, Bristol-Myers Squibb. “Sprycel remains an important therapy for many CML patients and we are committed to continuing its research in CML, with the goal of improving patient outcomes and informing medical practice.”
Related News
-
News CPHI Frankfurt 2022: Innovator Interview – DSM Biomedical
At CPHI Frankfurt we spoke to Anne-Cecile Bayne, Global Science & Innovation Lead Pharma and Medical Nutrition, and Marc Hendriks, Vice President Strategy & Business Development, on their expertise in nitrosamines and business strategy at DSM Biomedica... -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled. -
News Magic mushrooms could be used to treat mental health conditions
A compound found in magic mushrooms, psilocybin, could be used to treat mental health conditions and help patients suffering with severe depression, as shown by the results of the largest study of its kind to date. -
News UK-based partnership to launch DETERMINE study into rare cancer research
UK-based CRO Quanticate is set to partner with Cancer Research UK for the launch of the DETERMINE study focused on testing a range of existing and approved drugs and therapies on rare cancers. -
News FDA approves Thermo Fisher blood tests for wheat and sesame allergies
Both tests have been approved by the US regulator for in vitro diagnostic use -
News QIAGEN launches world’s first syndromic test for monkeypox
The test can distinguish between monkeypox and other diseases that cause similar symptoms. -
News Monkeypox Update: Vaccine shortage, sewage surveillance and global testing
As concern over the monkeypox outbreak continues to rise, we take a look at major developments from the first week of August. -
News CPHI Podcast Series: The importance of novel excipients for innovative drug development
The latest episode in the CPHI Podcast Series dives into the world of novel excipients and explores their importance for innovative drug development.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance